Objective-The effects of hormone replacement therapy (HRT) can affect many aspects relevant to cardiovascular disease, including vasomotor function, inflammation, and hemostasis. Recent studies have demonstrated that current doses of HRT exert a mixture of both protective and adverse effects. In the current study, we compared the effects of lower doses of HRT (L-HRT) and conventional doses of HRT (C-HRT) on a variety of relevant cardiovascular parameters. Methods and Results-This randomized, double-blind, crossover study included 57 women who received micronized progesterone 100 mg with either conjugated equine estrogen 0.625 mg (C-HRT) or 0.3 mg (L-HRT) daily for 2 months. L-HRT showed comparable effects to C-HRT on high-density lipoprotein cholesterol and triglyceride levels, but not on low-density lipoprotein cholesterol levels. C-HRT and L-HRT significantly improved the percent flow-mediated dilator response to hyperemia from baseline values (both PϽ0.001) by a similar degree (Pϭ0.719). C-HRT significantly increased high-sensitivity C-reactive protein ( Key Words: hormone replacement therapy Ⅲ lower doses Ⅲ endothelial function Ⅲ inflammation Ⅲ hemostasis Ⅲ menopause P rospective cohort surveys suggest that hormone replacement therapy (HRT) decreases the risk of coronary artery disease in relatively young and healthy postmenopausal women. 1,2 In contrast, 2 recent randomized studies, the Heart and Estrogen/progestin Replacement Study (HERS) 3 and the Women's Health Initiative (WHI), 4 reported that HRT did not reduce the risk of cardiovascular events and further demonstrated some trends toward an increased risk of cardiovascular events. The increased risk of coronary heart disease was surprising given that low-density lipoprotein (LDL) cholesterol levels decreased and that high-density lipoprotein (HDL) cholesterol levels increased. The reasons may result from the effects of HRT on C-reactive protein (CRP) levels and thromboembolism risk through activating coagulation pathways evidenced by decreased antithrombin III and increased prothrombin fragment 1ϩ2 (F1ϩ2). 5, 6 Activation of coagulation pathways has been detected dose-dependently in postmenopausal women treated with conjugated equine estrogen (CEE) 0.625 and 1.25 mg. 7 In this regard, we reported that conventional dosages of CEE 0.625 mg increased tissue factor activity and F1ϩ2, indicator of coagulation activation, 8, 9 and observational studies demonstrated that the risk for thromboembolism increases dosedependently in postmenopausal women. 2, 10, 11 The apparent protective effect of CEE in the Nurses' Health Study was noted only at the 0.3 mg and 0.625 mg doses; 1.25 mg and higher doses were not cardioprotective. 11 It has been reported that Ϸ59% of women discontinue HRT within 2 years, and the use of lower doses of HRT has been proposed to improve long-term compliance with HRT. 12 Recently, lower doses (CEE 0.3 mg) of HRT (L-HRT) demonstrated comparable effects to conventional doses (CEE 0.625 mg) of HRT (C-HRT) on menopausal symptoms, 13,14 endometrial protection, 15 plasma lipoproteins, carbohydrate metabolism, 16 and bone mineral density. 17, 18 The liver is a
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However, the effects of L-HRT on vasomotor function, inflammation marker CRP, and hemostasis markers in postmenopausal women have not been compared directly with C-HRT. Therefore, the purpose of this study was to determine the effects of C-HRT and L-HRT on vasomotor function, CRP, and hemostasis markers in postmenopausal women.
Methods

Study Population and Design
Sixty postmenopausal women participated in this study, all with plasma 17␤-estradiol levels Ͻ50 pg/mL and cessation of menses for at least 1 year. No subjects had used any cholesterol-lowering agent, estrogen therapy, antioxidant vitamin supplements, or angiotensinconverting enzyme inhibitors during the preceding 2 months. None had diabetes, was a smoker, or had previous angina. This study used a randomized, double-blind, crossover design. We used the National Heart, Lung, and Blood Institute's definitions 20 for overweight as the cutoff points: body mass index Ն25.0 and Ͻ30.0 kg/m 2 . We used World Health Organizations/International Society of Hypertension definitions 21 for hypertension defined as systolic and diastolic blood pressure Ն140 or Ն90 mm Hg, respectively. Severe and moderate hypertension was excluded to avoid drug effects. Thirty had hypertension and 13 women were overweight, and the other 17 women were normotensive and of normal weight. Sixty women received micronized progesterone (MP) 100 mg with either CEE 0.625 mg or 0.3 mg daily during 2 months, with a 2-month washout period because they did not undergo hysterectomy before. Two hypertensive and 1 overweight women in C-HRT withdrew because of severe vaginal bleeding. Thus, a total of 57 using C-HRT and L-HRT completed all phases of the study. The study was approved by the Gil Hospital Institute Review Board and all participants gave written, informed consent.
Laboratory Assays
Blood samples for laboratory assays and vascular studies were obtained at approximately 8:00 AM after an overnight fast, at each baseline, and at the end of each treatment period, and were immediately coded so that investigators performing laboratory assays were blinded to subject identity or study sequence. Assays for lipids, fibrinogen, antithrombin III, F1ϩ2, and plasminogen activator inhibitor type 1 (PAI-1) antigens were measured as previously described. 8, 9, [22] [23] [24] In all patients, plasma was collected for the measurement of high-sensitivity C-reactive protein (hsCRP) levels by commercially available kits (Immundiagnostik CRP ELISA test). The lower limit of detection was 0.0001 mg/dL.
All samples from the same patient (batch samples) were measured in blinded pairs on the same enzyme-linked immunosorbent assay kit to minimize run-to-run variability. The interassay and intra-assay coefficients of variation were Ͻ6%.
Vascular Studies
Imaging studies of the right brachial artery were performed using ATL HDI 3000 ultrasound machine equipped with a 10-MHz linear-array transducer, based on a previously published technique. 22, 23, 25 All images were transmitted to a personal computer via Ethernet with DICOM format (digital imaging and communication in medicine) and then saved on the hard disk of a personal computer as a BMP format. Arterial diameters were measured with Image Tool for Windows version 2.0 (University of Texas Health Science Center, San Antonio, Texas). Measurements were performed by 2 independent investigators (D.K.J. and H.S.K.) blinded to the subject's identity and medication status. Measurements of maximum diameter and percent flow-mediated dilation were performed in 10 studies selected at random. The interobserver and intraobserver variability for repeated measurement of maximum diameter were 0.004Ϯ0.039 mm and 0.005Ϯ0.089 mm, respectively. The interobserver and intraobserver variability for repeated measurement of percent flow-mediated dilation were 0.07Ϯ1.27% and 0.15Ϯ1.24%, respectively.
Statistical Analysis
Data are expressed as meanϮSEM or median (range: 25% to 75%). After testing data for normality, we used Student paired t test or Wilcoxon signed-rank test to compare values at each baseline and after each therapy and the relative changes in values in response to treatment, as reported in the Table. Pearson or Spearman correlation coefficient analysis was used to assess associations between measured parameters. We calculated that 50 subjects would provide 80% power for detecting difference of absolute increase, 1.5% or greater flow-mediated dilation of the brachial artery between baseline and L-HRT, with ␣ϭ0.05 based on our previous studies. 22, 23, 25 The comparison of endothelium-dependent dilation among C-HRT and L-HRT treatment schemes was prospectively designated as the primary end point. All other comparisons were considered secondary end points. P Ͻ0.05 was deemed as statistically significant.
Results
Baseline values before C-HRT or L-HRT treatment period were compared. No significant differences were noted (Table). To assess the possibility of a carryover effect from the initial treatment phase to the next treatment phase, we compared the baseline values before the first treatment phase with those before the second treatment phase. No significant differences were found. After 2 months of C-HRT or L-HRT treatment, plasma levels of 17␤-estradiol significantly increased from baseline values (Table) .
Effects of Therapies on Lipids
The effects of therapies on lipids are shown in the Table. C-HRT and L-HRT significantly reduced total cholesterol levels by 6Ϯ2% and 2Ϯ2%, respectively, from baseline values (PϽ0.001 and Pϭ0.038, respectively) and LDL cholesterol levels by 18Ϯ3% and 6Ϯ3%, respectively, from baseline values (PϽ0.001 and Pϭ0.003, respectively). C-HRT and L-HRT significantly increased triglyceride levels by 35Ϯ7% and 34Ϯ11%, respectively, from baseline values (Pϭ0.001 and Pϭ0.047, respectively) and HDL cholesterol levels by 10Ϯ2% and 6Ϯ2%, respectively, from baseline values (PϽ0.001 and Pϭ0.060, respectively). Compared with L-HRT, C-HRT significantly reduced LDL cholesterol levels (Pϭ0.005); otherwise, there were no significant differences between both.
Effects of Therapies on Vasomotor Function
Basal brachial artery diameter and forearm blood flows were similar during the 2 treatment periods, as were the peak brachial artery diameters and forearm blood flows during reactive hyperemia and the percent increase in flow during hyperemia (data not shown). C-HRT and L-HRT significantly improved the percent flow-mediated dilator response to hyperemia by 47Ϯ8% and 44Ϯ5%, respectively, from baseline values (both PϽ0.001; Figure 1 ) by a similar degree (Pϭ0.719). The brachial artery dilator response to nitroglycerin between each therapy was not significantly changed from baseline measurements (Pϭ0.220 and Pϭ0.159, respectively).
Effects of Therapies on hsCRP and Hemostasis
C-HRT significantly increased hsCRP by 149Ϯ27% from baseline values (PϽ0.001); however, L-HRT did not significantly change hsCRP (Pϭ0.874). The effects of C-HRT and L-HRT on hsCRP were significantly different (PϽ0.001). There were significant inverse correlations between pretreatment CRP levels and the degree of change in CRP after C-HRT (rϭϪ0.434, Pϭ0.001) and after L-HRT (rϭϪ0.496, PϽ0.001). C-HRT and L-HRT significantly decreased antithrombin III by 11Ϯ2% and 3Ϯ2%, respectively, from baseline values (PϽ0.001 and Pϭ0.042, respectively). C-HRT significantly reduced antithrombin III more than L-HRT (PϽ0.001). C-HRT significantly increased F1ϩ2 by 187Ϯ55% from baseline values (PϽ0.001); however, L-HRT did not significantly change F1ϩ2 (Pϭ0.558). The effects of C-HRT and L-HRT on F1ϩ2 were significantly different (PϽ0.001; Figure 2 ). There was no significant correlation between pretreatment F1ϩ2 levels and the degree of change in F1ϩ2 after C-HRT (rϭ0.151, Pϭ0.260) or L-HRT (rϭϪ0.264, Pϭ0.054). C-HRT and L-HRT significantly reduced plasma PAI-1 antigen levels by 12Ϯ6% and 2Ϯ6%, respectively, from baseline values (Pϭ0.002 and Pϭ0.038, respectively) to a similar degree (Pϭ0.184). There were significant inverse correlations between pretreatment PAI-1 levels and the degree of changes in PAI-1 after C-HRT (rϭϪ0.418, Pϭ0.002) and after L-HRT (rϭϪ0.513, PϽ0.001). Neither therapy significantly changed fibrinogen levels from baseline values.
There were significant correlations between body mass index and hsCRP levels before C-HRT and L-HRT (rϭ0.360, Pϭ0.008 and rϭ0.328, Pϭ0.017, respectively). However, there were no significant correlations between the degree of change in flow-mediated dilation and the degree of change in lipoprotein or CRP levels after C-HRT (Ϫ0.198ՅrՅ0.144) Data are expressed as meansϮSEM or range (25%-75%). CEEϩMPϭconjugated equine estrogen combined with micronized progesterone 100 mg (HRT). B indicates baseline; H, hormone replacement therapy.
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and after L-HRT (Ϫ0.162ՅrՅ0.212). There were no significant correlations between pretreatment triglyceride levels and pretreatment PAI-1 levels. However, there were significant correlations between body mass index and pretreatment PAI-1 levels (rϭ0.303, Pϭ0.027). There were no significant correlations between the degree of change in antithrombin III or F1ϩ2 and the degree of change in PAI-1 antigen levels after C-HRT (0.020ՅrՅ0.041) and after L-HRT (Ϫ0.048ՅrՅ0.009).
Discussion
We have previously shown that C-HRT improved nitric oxide bioavailability, reduced circulating levels of markers of inflammation, 22, 25 and improved fibrinolysis potential 24, 26 in postmenopausal women. However, we and others have reported that C-HRT increased hsCRP levels 9,27,28 and thromboembolism risk through activating coagulation system. However, no studies have directly compared the effects of C-HRT and L-HRT on vascular function. In the current study, we demonstrate comparable effects of L-HRT and C-HRT on both HDL cholesterol and triglycerides, although the effects were not comparable on LDL cholesterol levels, consistent with previous reports. 16, 18 We also observed comparable effects of L-HRT and C-HRT on flow-mediated dilation, which also was consistent with a previous report. 29 -31 We observed hsCRP levels were significantly correlated with body mass index, which are consistent with another study. 32 We observed that in contrast to C-HRT, L-HRT did not significantly increase hsCRP levels. These different effects of C-HRT and L-HRT may be clinically very relevant. Epidemiologic studies have consistently shown that elevated CRP is a risk factor for coronary heart disease among women. 33 CRP increases the expression of tissue factor 34 and adhesion molecules, 35 promotes monocyte chemotaxis, 36 and decreases endothelial nitric oxide synthase expression and activity. 37 In addition, CRP may contribute to atherogenesis by facilitating uptake of LDL by macrophages, thus accelerating foam cell formation. 38 Tissue factor activates the extrinsic coagulation cascade, providing a link between inflammation and thrombosis. In this regard, we recently reported that C-HRT significantly increased CRP and tissue factor activity and increased thrombosis in postmenopausal women. 9 These observations have led many investigators to suggest that the disappointing results of the recent clinical trials may be caused in part by C-HRT-induced increases in hsCRP. 3, 39, 40 Of interest, we observed that the highest pretreatment CRP levels increased to the least extent after C-HRT.
We observed that C-HRT significantly reduced antithrombin III and increased F1ϩ2 levels, consistent with others. 7 Of note, we observed that the effects of L-HRT on antithrombin III were significantly less than C-HRT; furthermore, like hsCRP, L-HRT did not significantly increase F1ϩ2 levels. We also observed that L-HRT had comparable effects to C-HRT regarding PAI-1 antigen levels, suggesting an improvement of fibrinolysis potential. 6, 26 Furthermore, the highest pretreatment PAI-1 antigen levels decreased to the greatest extent than the lowest pretreatment PAI-1 antigen levels after C-HRT and L-HRT. These observations are consistent with our previous reports 24, 26 and that of others. 16 However, there were no significant correlations between the effects of HRT on coagulation and fibrinolysis markers, which are consistent with our previous reports 9, 24 and others. 41, 42 Scarabin et al 41 reported no correlation between fibrinolytic potential and coagulation activation using C-HRT regimens. Cushman et al 42 found that hemostasis markers and evidence of procoagulation were not associated and fibrinolytic potential increased. Taken together, L-HRT may increase fibrinolysis potential with little changes on coagulation, unlike C-HRT.
The liver is a major source of coagulants, CRP, and PAI-1. 19, 43 Thus, the presence of estrogen in different concentrations in the portal circulation, after absorption from the gut, may show different synthesis of coagulants and CRP, although no mechanism of such an effect has been proposed. Accordingly, L-HRT might not demonstrate exactly the same effects as C-HRT.
In summary, we observed that L-HRT has comparable effects to C-HRT on lipoproteins, flow-mediated dilation, and PAI-1 antigen levels. However, L-HRT did not increase hsCRP or F1ϩ2 levels, and it decreased antithrombin III less than C-HRT. Therefore, L-HRT may be considered as an alternative to C-HRT in postmenopausal women. However, clinical recommendations regarding the effects of L-HRT on cardiovascular outcomes must await the performance of additional studies with clinical end points.
